{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:31:13Z","timestamp":1788985873064,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2015,10,3]],"date-time":"2015-10-03T00:00:00Z","timestamp":1443830400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Prostate Cancer Foundation Young Investigator Award 2013"},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81300627"],"award-info":[{"award-number":["81300627"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s11255-015-1125-7","type":"journal-article","created":{"date-parts":[[2015,10,3]],"date-time":"2015-10-03T07:24:28Z","timestamp":1443857068000},"page":"1779-1788","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["The safety and efficiency of onabotulinumtoxinA for the treatment of overactive bladder: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"47","author":[{"given":"Yi","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,3]]},"reference":[{"key":"1125_CR1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","volume":"61","author":"P Abrams","year":"2003","unstructured":"Abrams P, Cardozo L, Fall M et al (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61:37\u201349","journal-title":"Urology"},{"key":"1125_CR2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/nau.20737","volume":"28","author":"P Abrams","year":"2009","unstructured":"Abrams P, Artibani W, Cardozo L et al (2009) Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn 28:297","journal-title":"Neurourol Urodyn"},{"key":"1125_CR3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0090-4295(99)00492-6","volume":"55","author":"C Chapple","year":"2000","unstructured":"Chapple C (2000) Muscarinic receptor antagonist in the treatment of overactive bladder. Urology 55:33\u201346","journal-title":"Urology"},{"key":"1125_CR4","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1016\/j.juro.2012.09.079","volume":"188","author":"EA Gormley","year":"2012","unstructured":"Gormley EA, Lightner DJ, Faraday M et al (2012) Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment. J Urol 188:2455","journal-title":"J Urol"},{"key":"1125_CR5","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0022-5347(05)67283-7","volume":"164","author":"B Schurch","year":"2000","unstructured":"Schurch B, St\u00f6hrer M, Kramer G et al (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164:592","journal-title":"J Urol"},{"key":"1125_CR6","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eururo.2008.09.009","volume":"55","author":"A Apostolidis","year":"2009","unstructured":"Apostolidis A, Dasgupta P, Denys P et al (2009) Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol 55:100\u2013119","journal-title":"Eur Urol"},{"key":"1125_CR7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.eururo.2007.10.013","volume":"53","author":"G Karsenty","year":"2008","unstructured":"Karsenty G, Denys P, Amarenco G et al (2008) Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity\/neurogenic overactive bladder: a systematic literature review. Eur Urol 53:275\u2013287","journal-title":"Eur Urol"},{"key":"1125_CR8","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1123654","volume":"312","author":"M Dong","year":"2006","unstructured":"Dong M, Yeh F, Tepp WH et al (2006) SV2 is the protein receptor for botulinum neurotoxin A. Science 312:592\u2013596","journal-title":"Science"},{"issue":"212","key":"1125_CR9","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0022-3565(25)31908-7","volume":"1980","author":"L Simpson","year":"1980","unstructured":"Simpson L (1980) Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther 1980(212):16\u201321","journal-title":"J Pharmacol Exp Ther"},{"key":"1125_CR10","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/01.ju.0000169481.42259.54","volume":"174","author":"A Apostolidis","year":"2005","unstructured":"Apostolidis A, Popat R, Yiangou Y et al (2005) Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intra-detrusor injections of botulinum toxin for human detrusor overactivity. J Urol 174:977\u2013982","journal-title":"J Urol"},{"key":"1125_CR11","unstructured":"Higgins J, Green S (2011) Cochrane handbook for systematic reviews of interventions version 5.1.4 (updated March 2011). The Cochrane collaboration 2011. http:\/\/www.cochrane-handbook.org Accessed 27 Feb 2012"},{"key":"1125_CR12","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. BMJ 339:b2535","journal-title":"BMJ"},{"key":"1125_CR13","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","volume":"64","author":"C Chapple","year":"2013","unstructured":"Chapple C, Sievert KD, MacDiarmid S et al (2013) OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol 64:249\u2013256","journal-title":"Eur Urol"},{"key":"1125_CR14","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.juro.2014.07.008","volume":"192","author":"YC Chuang","year":"2014","unstructured":"Chuang YC, Kaufmann JH, Chancellor DD et al (2014) Bladder instillation of liposome encapsulated onabotulinumtoxinA improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial. J Urol 192:1743\u20131749","journal-title":"J Urol"},{"key":"1125_CR15","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.eururo.2011.10.028","volume":"61","author":"P Denys","year":"2012","unstructured":"Denys P, Le Normand L, Ghout I et al (2012) Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study. Eur Urol 61:520\u2013529","journal-title":"Eur Urol"},{"key":"1125_CR16","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.juro.2010.08.021","volume":"184","author":"R Dmochowski","year":"2010","unstructured":"Dmochowski R, Chapple C, Nitti VW et al (2010) Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol 184:2416\u20132422","journal-title":"J Urol"},{"key":"1125_CR17","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.juro.2012.12.022","volume":"189","author":"VW Nitti","year":"2013","unstructured":"Nitti VW, Dmochowski R, Herschorn S et al (2013) OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol 189:2186\u20132193","journal-title":"J Urol"},{"key":"1125_CR18","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/nau.21021","volume":"30","author":"E Rovner","year":"2011","unstructured":"Rovner E, Kennelly M, Schulte-Baukloh H et al (2011) Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn 30:556\u2013562","journal-title":"Neurourol Urodyn"},{"key":"1125_CR19","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.eururo.2011.12.056","volume":"62","author":"DG Tincello","year":"2012","unstructured":"Tincello DG, Kenyon S, Abrams KR et al (2012) Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study). Eur Urol 62:507\u2013514","journal-title":"Eur Urol"},{"key":"1125_CR20","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","volume":"20","author":"WF Stewart","year":"2003","unstructured":"Stewart WF, Van Rooyen JB, Cundiff GW et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20:327\u2013336","journal-title":"World J Urol"},{"key":"1125_CR21","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","volume":"54","author":"CR Chapple","year":"2008","unstructured":"Chapple CR, Khullar V, Gabriel Z et al (2008) The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 54:543\u2013562","journal-title":"Eur Urol"},{"key":"1125_CR22","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1524-4733.2005.00041.x","volume":"8","author":"YF Yu","year":"2005","unstructured":"Yu YF, Nichol MB, Yu AP et al (2005) Persistence and adherence of medications for chronic overactive bladder\/urinary incontinence in the California medicaid program. Value Health 8:495\u2013505","journal-title":"Value Health"},{"key":"1125_CR23","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.eururo.2005.12.010","volume":"49","author":"A Apostolidis","year":"2006","unstructured":"Apostolidis A, Dasgupta P, Fowler CJ (2006) Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 49:644\u2013650","journal-title":"Eur Urol"},{"key":"1125_CR24","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.juro.2007.01.130","volume":"177","author":"A Sahai","year":"2007","unstructured":"Sahai A, Khan M, Dasgupta P (2007) Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 177:2231\u20132236","journal-title":"J Urol"},{"key":"1125_CR25","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.juro.2009.03.083","volume":"182","author":"YC Chuang","year":"2009","unstructured":"Chuang YC, Tyagi P, Huang CC et al (2009) Urodynamic and immunohistochemical evaluation of intra- vesical botulinum toxin A delivery using liposomes. J Urol 182:786","journal-title":"J Urol"},{"key":"1125_CR26","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1442-2042.2011.02946.x","volume":"19","author":"T Yokoyama","year":"2012","unstructured":"Yokoyama T, Chancellor MB, Oguma K et al (2012) Botulinum toxin type A for the treatment of lower urinary tract disorders. Int J Urol 19:202\u2013215","journal-title":"Int J Urol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-015-1125-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-015-1125-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-015-1125-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T22:22:46Z","timestamp":1748643766000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-015-1125-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,3]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["1125"],"URL":"https:\/\/doi.org\/10.1007\/s11255-015-1125-7","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,3]]}}}